Most Read Articles
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
05 Oct 2019
The combination of sofosbuvir and velpatasvir is safe and effective for the treatment of hepatitis C virus (HCV) in patients with end-stage renal disease (ESRD) undergoing haemodialysis, a study has shown.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Water-free cyclosporine formulation safe, effective for dry eye disease

17 Jun 2019

Treatment with water-free cyclosporine formulation (CyclASol) at either 0.1% or 0.05% concentration is tolerable and provides effective relief of the signs of dry eye disease (DED), according to data from a phase II study.

The study randomly assigned 207 DED patients (mean age, 62.4 years; 73.9 percent female) to one of the following treatment arms: CyclASol 0.05% (n=51), CyclASol 0.1% (n=51), vehicle (n=52) and cyclosporine emulsion (n=53). Dosed twice daily, the 16-week treatment was initiated after a 2-week run-in period.

Efficacy endpoints included total and subregion corneal fluorescein staining, conjunctival staining, visual analogue scale (VAS) for dry eye symptoms, VAS severity, and Ocular Surface Disease Index (OSDI) questionnaire scores.

During the 16-week treatment period, CyclASol consistently reduced corneal and conjunctival staining compared with both the vehicle and emulsion. The onset of effect occurred early at day 14.

In mixed-effects model–based approach, the effect of CyclASol was statistically significant compared with that of the vehicle (total corneal staining, p<0.1; central corneal staining, p<0.001; conjunctival staining, p<0.01). CyclASol also demonstrated a significant effect on OSDI as symptom parameter (p<0.01).

Dryness symptoms, as measured by VAS, improved across all treatment arms, with no significant difference between CyclASol and vehicle.

In terms of safety, the rate of ocular adverse events was low in all treatment arms. Treatment-emergent adverse events were reported in 65 patients (31.4 percent) overall, all of which were mild-to-moderate in severity.

The present data show that the new water-free cyclosporine formulation relieves the signs of DED as early as after 2 weeks of treatment, with excellent safety, tolerability and comfort profile, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
05 Oct 2019
The combination of sofosbuvir and velpatasvir is safe and effective for the treatment of hepatitis C virus (HCV) in patients with end-stage renal disease (ESRD) undergoing haemodialysis, a study has shown.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.